Madrigal Pharmaceuticals (MDGL) Expected to Announce Quarterly Earnings on Thursday

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) is projected to announce its Q3 2025 results before the market opens on Thursday, October 30th. Analysts expect the company to announce earnings of ($2.01) per share and revenue of $244.3320 million for the quarter. Investors can check the company's upcoming Q3 2025 earningsummary page for the latest details on the call scheduled for Tuesday, November 4, 2025 at 8:00 AM ET.

Madrigal Pharmaceuticals (NASDAQ:MDGL - Get Free Report) last announced its earnings results on Tuesday, August 5th. The biopharmaceutical company reported ($1.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.48) by $1.58. The company had revenue of $212.80 million during the quarter, compared to analysts' expectations of $158.94 million. Madrigal Pharmaceuticals had a negative net margin of 54.68% and a negative return on equity of 38.38%. The firm's quarterly revenue was up 1357.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($7.10) earnings per share. On average, analysts expect Madrigal Pharmaceuticals to post $-23 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Madrigal Pharmaceuticals Stock Performance

Shares of MDGL opened at $415.95 on Thursday. The company has a current ratio of 5.11, a quick ratio of 4.78 and a debt-to-equity ratio of 0.17. The stock has a market cap of $9.23 billion, a P/E ratio of -32.37 and a beta of -1.02. The company has a 50-day moving average of $428.62 and a two-hundred day moving average of $346.46. Madrigal Pharmaceuticals has a 12-month low of $200.63 and a 12-month high of $463.63.

Insider Activity

In related news, Director Paul A. Friedman sold 129,172 shares of the company's stock in a transaction that occurred on Wednesday, August 13th. The shares were sold at an average price of $370.24, for a total transaction of $47,824,641.28. Following the completion of the transaction, the director owned 187,164 shares of the company's stock, valued at approximately $69,295,599.36. This represents a 40.83% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO William John Sibold sold 7,616 shares of the company's stock in a transaction that occurred on Thursday, August 21st. The stock was sold at an average price of $400.18, for a total transaction of $3,047,770.88. Following the transaction, the chief executive officer directly owned 109,753 shares of the company's stock, valued at $43,920,955.54. This trade represents a 6.49% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have acquired 165,683 shares of company stock valued at $61,921,142 and have sold 248,642 shares valued at $91,388,103. 21.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE grew its stake in Madrigal Pharmaceuticals by 12.7% during the second quarter. Bank of America Corp DE now owns 277,221 shares of the biopharmaceutical company's stock worth $83,898,000 after buying an additional 31,260 shares during the period. BNP Paribas Financial Markets grew its stake in Madrigal Pharmaceuticals by 1,886.1% during the second quarter. BNP Paribas Financial Markets now owns 69,037 shares of the biopharmaceutical company's stock worth $20,893,000 after buying an additional 65,561 shares during the period. Raymond James Financial Inc. grew its stake in Madrigal Pharmaceuticals by 1.9% during the second quarter. Raymond James Financial Inc. now owns 54,933 shares of the biopharmaceutical company's stock worth $16,625,000 after buying an additional 1,017 shares during the period. Balyasny Asset Management L.P. grew its stake in Madrigal Pharmaceuticals by 26.8% during the second quarter. Balyasny Asset Management L.P. now owns 34,500 shares of the biopharmaceutical company's stock worth $10,441,000 after buying an additional 7,285 shares during the period. Finally, The Manufacturers Life Insurance Company grew its stake in Madrigal Pharmaceuticals by 2.1% during the second quarter. The Manufacturers Life Insurance Company now owns 23,416 shares of the biopharmaceutical company's stock worth $7,087,000 after buying an additional 471 shares during the period. Institutional investors and hedge funds own 98.50% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on MDGL shares. HC Wainwright started coverage on shares of Madrigal Pharmaceuticals in a research report on Thursday, September 4th. They set a "buy" rating and a $500.00 target price for the company. Cowen reissued a "buy" rating on shares of Madrigal Pharmaceuticals in a research report on Tuesday, August 26th. Canaccord Genuity Group boosted their price objective on shares of Madrigal Pharmaceuticals from $428.00 to $526.00 and gave the company a "buy" rating in a research report on Friday, September 12th. Truist Financial started coverage on shares of Madrigal Pharmaceuticals in a research report on Tuesday, October 14th. They issued a "buy" rating and a $580.00 price objective for the company. Finally, TD Cowen boosted their price objective on shares of Madrigal Pharmaceuticals from $390.00 to $554.00 and gave the company a "buy" rating in a research report on Tuesday, August 26th. Eleven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Madrigal Pharmaceuticals currently has a consensus rating of "Moderate Buy" and an average price target of $532.70.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.